That's why OpenAI's push to own the developer ecosystem end-to-end matters in26. "End-to-end" here doesn't mean only better models. It means the ...
Pfizer is leaving no stone unturned in its efforts to prevent Novo Nordisk from stealing off with Metsera, the weight-loss therapy developer it is hoping to acquire in a deal worth up to $7.3 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results